Ad Header

PharmaLive

Slogan

The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

AstraZeneca succeeds in treating lupus in late-stage study

AstraZeneca Plc’s experimental treatment anifrolumab significantly reduced disease activity in patients with the autoimmune disorder lupus in a late-stage study.

Read More »

Bio-Thera gets approval for Humira biosimilar in China

China’s Bio-Thera Solutions Ltd. won a regulatory approval for the company’s version of AbbVie Inc.’s blockbuster rheumatoid arthritis treatment Humira, paving the way for the first such biosimilar to enter the world’s second-largest drug market.

Read More »

Healthline Media Partners with Healthcare Influencer Nitika Chopra to Present Chronicon

Almost no health topic was off limits at Chronicon, a first-of-its kind day-long event that brought together today’s most impactful health influencers specializing in chronic health conditions for an open forum to address the needs of those living with chronic conditions and their support communities.

Read More »

Gilead and Galapagos’ JAK Inhibitor Stumbles in Mid-Stage Lupus Trial

Despite the success Gilead Sciences has experienced with the JAK inhibitor filgotinib in rheumatoid arthritis, the medication failed to hit the mark in mid-stage trials aimed at lupus and Sjogren’s syndrome.

Read More »

J&J’s Tremfya Shows Extended Success in Treating Plaque Psoriasis

J&J’s Janssen Pharmaceutical released new long-term data from the open-label period of the Phase III VOYAGE 1 study.

Read More »

Novartis Inks Collaboration & Option Deal with IFM Due

IFM Therapeutics subsidiary IFM Due and Novartis will develop a group of immunotherapies that inhibit the cGAS/STING pathway to treat a broad range of inflammatory and autoimmune diseases.

Read More »

AstraZeneca lupus drug shows promise after setback

AstraZeneca’s experimental drug to treat moderate-to-severe lupus met the main goal in a late-stage trial. During 2018, anifrolumab failed to meet the primary target in the final stage of another study.

Read More »

FDA Approves AbbVie’s RA Drug Rinvoq

AbbVie’s Rinvoq was approved by the FDA for treating adults with moderately to severely active rheumatoid arthritis (RA) who have had an inadequate response or intolerance to methotrexate.

Read More »

European Medicines Agency Validates Marketing Application for Filgotinib for the Treatment of Rheumatoid Arthritis

Gilead Sciences Inc. and Galapagos NV announced that the Marketing Authorization Application for filgotinib – an investigational, oral, selective JAK1 inhibitor for the treatment of adults with rheumatoid arthritis – was validated and is under evaluation by the European Medicines Agency.

Read More »

Top 200 Medicines Annual Report 2019: The king of medicines

Humira’s dominance continues as the world’s top-selling prescription product as the biologic therapy is the first drug to exceed $20 billion in annual global sales.

Read More »

Ad Right Top

MedAdNews

Extensive pharmaceutical business and marketing intelligence. For back issues, please contact MDAD@kmpsgroup.com.

October 2019 Focus: Top 50 Company Profiles & Financials, Outcomes Creativity Index, and more!

Subscribe

Ad Right Bottom